Search Results
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Primoris Services Corporation of Class Action Lawsuit and Upcoming Deadlines - PRIM
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Primoris Services Corporation ("Primoris" or the "Company") (NYSE: PRIM). Such investors are advised to contact
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX
performance. On this news, Beta Bionics' stock price fell approximately 37%.On January 30, 2026, Beta Bionics filed a Form 8-K that disclosed that the FDA had sent Beta Bionics a warning letter connected to its earlier Form 483, acknowledging that the FDA's concerns were more serious than the minor
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
the Company issued a press release discussing the FDA's response letter for the RP1 BLA. In the press release, Replimune conceded that "a randomized controlled trial was preferred" by the FDA, but also claimed that the FDA communicated that "if the data was sufficiently compelling, a single arm trial
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wise Group plc of Class Action Lawsuit and Upcoming Deadlines - WSE
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Wise Group plc ("Wise" or the "Company") (NASDAQ: WSE). Such investors are advised to contact Danielle Peyton
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'" The FTC complaint also includes allegations that Hims & Hers "shared consumers' sensitive health
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
submitted its Biologics License Application ("BLA") to the U.S. Food and Drug Administration for Deramiocel as a cell therapy for the treatment of Duchenne muscular dystrophy. In July 2025, the FDA issued a Complete Response Letter because it could not approve the BLA in its current form. According to the Company,
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in HDFC Bank Limited of Class Action Lawsuit and Upcoming Deadlines - HDB
make large deposits with the Company. The Company offered 6.01% interest to MSRDC, a 2.51% markup over the interest offered to other savings accounts, and paid that markup by "disguis[ing] [it] as sponsorship payments for a road safety awareness campaign run by MSRDC." Reportedly, an internal probe in March
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Smartsheet, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMAR
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Smartsheet, Inc. ("Smartsheet" or the "Company") (NYSE: SMAR). Such investors are advised to contact Danielle
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in EquipmentShare.com Inc. of Class Action Lawsuit and Upcoming Deadlines - EQPT
35,075,000 shares of common stock priced at $24.50 per share. Then, on June 24, 2026, Umibōzu Research ("Umibōzu") published a short report entitled "EquipmentShare: Relentless Self-Dealing, a Tech Veneer, and the Missouri 'Cult' That Started It All". The report alleged, among other things, that
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in York Space Systems, Inc. of Class Action Lawsuit and Upcoming Deadlines - YSS
Wolfpack Research published a short report entitled "YSS: Lost In Space – The Pentagon Just Killed 96% of York's Revenue". The Wolfpack report alleges that the Pentagon's decision to eliminate its Space Development Agency ("SDA") Tranche 3 Transport Layer—a program responsible for the majority
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment inPentair plc of Class Action Lawsuit and Upcoming Deadlines - PNR
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pentair plc ("Pentair" or the "Company") (NYSE: PNR). Such investors are advised to contact Danielle Peyton
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pentair plc of Class Action Lawsuit and Upcoming Deadlines - PNR
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pentair plc ("Pentair" or the "Company") (NYSE: PNR). Such investors are advised to contact Danielle Peyton
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET Taiwan Powers the AI Era at Taiwan Expo USA 2026 with Smart Manufacturing and Energy Solutions
Among the Expo's key showcases, the AI Manufacturing Pavilion and Smart Energy Pavilion will be located side by side on the show floor, forming a 260-square-meter showcase of Taiwan's capabilities across advanced manufacturing, AI infrastructure, and energy ecosystem.As AI investment accelerates
More news about: Taiwan External Trade Development Council (TAITRA)
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of JinkoSolar Holding Co., Ltd. - JKS
the class action]On April 16, 2026, JinkoSolar reported fourth quarter 2025 financial results, including a non-cash impairment charge exceeding $200 million that drove a $214.5 million GAAP loss. These results were at odds with various statements by JinkoSolar's officers during the Company's
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bloom Energy Corporation of Class Action Lawsuit and Upcoming Deadlines - BE
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bloom Energy Corporation ("Bloom" or the "Company") (NYSE: BE). Such investors are advised to contact Danielle
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in XTI Aerospace, Inc. of Class Action Lawsuit and Upcoming Deadlines - XTIA
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against XTI Aerospace, Inc. ("XTI" or the "Company") (NASDAQ: XTIA). Such investors are advised to contact Danielle Peyton
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alibaba Group Holding Limited of Class Action Lawsuit and Upcoming Deadlines - BABA
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alibaba Group Holding Limited ("Alibaba" or the "Company") (NYSE: BABA). Such investors are advised to contact
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Taboola.com Ltd. of Class Action Lawsuit and Upcoming Deadlines - TBLA
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Taboola.com Ltd. ("Taboola" or the "Company") (NASDAQ: TBLA). Such investors are advised to contact Danielle
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Babcock & Wilcox Enterprises, Inc. of Class Action Lawsuit - BW
YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP. If you are an investor who believes that you may have incurred a loss regarding your Babcock & Wilcox Enterprises, Inc. securities ("B & W" or the "Company") (NYSE: BW); such investors are advised to contact
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
for information about joining the class action]On August 24, 2026, Azenta issued a press release announcing the resignation of John Marotta from his roles as Chief Executive Officer and as a director of the Company. On this news, Azenta's stock price fell $4.52 per share, or 12.09%,
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
here for information about joining the class action]On August 28, 2026, a news site reported that the Company's phase 3 clinical trial for Galinpepimut-S (GPS) had reached its 80th patient death, a pre-specified event that was to trigger the release of results for the clinical trial. However,
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
information about joining the class action]On August 10, 2026, Sionna issued a press release "report[ing] topline data from two nucleotide binding domain 1 (NBD1) stabilizer programs, the PreciSION CF Phase 2a proof-of-concept (POC) trial of SION-719 when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor)
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
2026, Tyra issued a press release "announc[ing] initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)." While the Company said that the data indicated a favorable safety
More news about: Pomerantz LLP
Sep 17, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Beam issued a press release "announc[ing] updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD)." Although the Company said that "treatment with single-dose BEAM-302 was well tolerated with an acceptable safety profile in both Part A and Part B cohorts",
More news about: Pomerantz LLP